Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.

Achieve Life Sciences Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on C4 Therapeutics (CCCC) and Achieve Life Sciences (AC...

Wall Street Analysts Are Bullish on Top Healthcare Picks

In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Achieve Life Sciences, with a price target of $12.00. Ac...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACHV	$4.56	-2.77%	778.11K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACHV	$4.56	-2.8%	778.11K
3
4
5
6

ACHV

ACHV

Dividend Overview

Get Achieve Life Sciences Inc. Data in Excel

Get Achieve Life Sciences Inc. Data in Excel